Bernadette M. Connaughton's most recent trade in Halozyme Therapeutics Inc. was a trade of 2,977 Common Stock done at an average price of $73.6 . Disclosure was reported to the exchange on Sept. 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc | Bernadette M. Connaughton | Director | Sale of securities on an exchange or to another person at price $ 73.62 per share. | 02 Sep 2025 | 2,977 | 47,875 (0%) | 0% | 73.6 | 219,161 | Common Stock |
| Halozyme Therapeutics Inc | Bernadette M. Connaughton | Director | Sale of securities on an exchange or to another person at price $ 74.11 per share. | 02 Sep 2025 | 923 | 46,952 (0%) | 0% | 74.1 | 68,404 | Common Stock |
| Halozyme Therapeutics Inc | Bernadette M. Connaughton | Director | Sale of securities on an exchange or to another person at price $ 71.71 per share. | 02 Sep 2025 | 100 | 50,852 (0%) | 0% | 71.7 | 7,171 | Common Stock |
| Editas Medicine Inc | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 37,500 | 37,500 | - | - | Stock Option (right to buy) | |
| Halozyme Therapeutics Inc | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 5,750 | 5,750 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 4,165 | 50,952 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Halozyme Therapeutics Inc | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 8,804 | 8,804 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 6,501 | 46,787 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Syneos Health Inc - Ordina... | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 4,863 | 14,778 (0%) | 0% | 0 | Class A Common Stock | |
| Halozyme Therapeutics Inc | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 11,371 | 11,371 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 8,065 | 40,286 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc | Bernadette M. Connaughton | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Nov 2022 | 5,998 | 32,221 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Syneos Health Inc - Ordina... | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 2,839 | 9,915 (0%) | 0% | 0 | Class A Common Stock | |
| Editas Medicine Inc | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2021 | 24,732 | 24,732 | - | - | Stock Option (right to buy) | |
| Syneos Health Inc - Ordina... | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 2,364 | 7,076 (0%) | 0% | 0 | Class A Common Stock | |
| Halozyme Therapeutics Inc | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 5,230 | 32,013 | - | 0 | Restricted Stock Units |